ClinicalTrials.gg
RecruitingNCT05759468DKDUpdated Apr 13, 2026

NAD Augmentation in Diabetes Kidney Disease

A Phase 2 interventional study of Investigational Product - MIB 626 and Placebo in Type2diabetes and Diabetic Kidney Disease, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Planned enrollment
35th of 120
156 · median 79
Started
2023
with 6 others
Phase 2
54 of 153
5 open now
Primary completion
2026-11
later than 8 of 30 live
Registered
134th of 153
by date

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 35th largest by planned enrollment of the 120 interventional ones that give a count, is one of 7 that started in 2023, is one of 54 in phase 2, reaches primary completion later than 8 of the 30 other live ones, and was the 134th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

Read the detailed description

This will be two centers, randomized, double-blind, placebo-controlled, parallel group trial to determine whether βNMN, after its daily oral administration, is associated with a greater reduction in the UACR compared to placebo.

The trial will enroll community-dwelling older adults, 60 years or older, with type 2 diabetes mellitus (T2DM) and urine albumin to creatinine excretion ratio > 100 mg/ g creatinine.

03

Conditions studied

  • Type2diabetes
  • Diabetic Kidney Disease

Keywords

  • diabetes
  • type 2 diabetes
  • kidney disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A man or a woman (complete cessation of menses for one or more years and /or FSH > 20 U/L), 30 years or older
  2. Has type 1 or type 2 diabetes mellitus, as indicated by any of the following:

    1. Self-report of type 1 or type 2 diabetes plus the use of a prescribed medication.
    2. ICD-10 code for type 1 or type 2 diabetes plus current use of a medication in the electronic medical record.
    3. >6.4%; or 2 fasting glucose > 125 mg/dL
  3. Has an average of two or more morning UACR equal to or above 100mg/g creatinine each of which must be equal to or greater than 60 mg / g creatinine with at least one UACR value measured during the screening visit.

    a. Recent UACR value in the medical record within the preceding 3 months prior to screening is acceptable.

  4. If type 2 diabetic and UACR is > 300 mg/g creatinine, must be currently using an ACE inhibitor or an ARB or a SGLT2 inhibitor.
  5. > 25 mL/ min / 1.73 m2
  6. Hemoglobin A1c \<10%
  7. Able to speak English or Spanish or Haitian Creole
  8. Willing and able to provide written
  9. In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months.

Exclusion criteria

Exclusion criteria:

  1. Fasting morning UACR > 5,000 mg/ g creatinine
  2. Other laboratory abnormalities:

    1. Has or ALT > 3 times the
    2. \< 25 mL/ min / 1.73 m2
    3. Hematocrit \< 0.34 or > 0.50 L/L
  3. A major adverse cardiovascular event in preceding 3 months
  4. Participation in an trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
  5. Current alcohol or substance use disorder or dependence (DSM 5 criteria).
  6. Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures.
  7. An acute illness, including COVID-19, requiring hospitalization within the past 3 months or any acute illness, including COVID-19, within the past month.
  8. Has a history of anaphylaxis from vitamin B3 derivatives
  9. > 42.5 kg/ m2
  10. If patient has a confirmed diagnosis of type 3 diabetes, or gestational diabetes.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Active comparator
    Investigational Product - MIB 626

    The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

    Drug: Investigational Product - MIB 626

  • Placebo comparator
    Placebo

    Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.

    Drug: Placebo

Interventions

  • DrugNicotinamide MononucleotideStudies of Nicotinamide MononucleotideNicotinamide Mononucleotide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.

    Also known as: NMN

  • DrugPlacebo

    Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.

    Also known as: Placebo for NMN

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the change from baseline in UACR over the 6-month intervention period.

    To determine whether treatment with a microcrystalline formulation of β nicotinamide mononucleotide (βNMN) in older adults with DKD improves urinary albumin to creatinine excretion ratio (UACR), compared to placebo.

    Time frame: 6 months

Secondary outcomes

  1. Assess the proportion of participants in the two study arms with 30% or greater reduction in UACR

    In supportive analysis of the primary outcome, the investigator will compare the proportion of participants in the two study arms with 30% or greater reduction in UACR

    Time frame: 6 months

  2. Assess the change from baseline over the 6-month intervention period in biomarkers of kidney injury.

    Compared to placebo treatment, NMN treatment of older adults with DKD will assess for improvements in biomarkers of kidney injury in association with DKD prognosis by measuring KIM-1 and STNFR1 combinedly.

    Time frame: 6 month

  3. Change from baseline in the levels of serum creatinine over 6-month intervention period

    To determine whether NMN treatment is associated with change in serum creatinine from baseline to 24 weeks between the two study arms.

    Time frame: 6 month

  4. Change from baseline in the levels of cystine C over 6-month intervention period.

    To determine whether NMN treatment is associated with change in cystatin C from baseline to 24 weeks between the two study arms.

    Time frame: 6 month

  5. To determine whether NMN treatment is associated with significantly greater improvement in muscle endurance.

    Assess the change from baseline in muscle endurance by exercises (reps to failure) using Keiser Machines

    Time frame: 6 month

  6. Assess the change from baseline in performance-based measures of function.

    To determine whether NMN treatment is associated with significantly greater improvement in performance based by using 6-minute walking distance measure of function.

    Time frame: 6 month

  7. To determine whether NMN alters the circulating biomarkers of aging that the geroscience experts have recommended.

    Compared to placebo treatment, NMN treatment will be assessed to identify greater changes in the circulating biomarkers of aging. the biomarkers that will be assessed are IL6 and TNFalpha

    Time frame: 6 months

  8. Assess the change from baseline in the levels of NMN in the peripheral blood and in the PBMCs using a validated LC-MS/MS assay.

    NMN treatment will be assessed to determine significant increases in blood levels of NAD and its metabolome during the 24-week intervention period. The increase in NAD levels are to be observed during the intervention period in NMN-treated subjects that will be sustained during the 12-week follow-up period (legacy effect).

    Time frame: 6 months

  9. Assess the change in measure of H1bac as a measure of glycemic control over the 6 months intervention period.

    To determine the effect of NMN treatment on Hb1ac (expressed in mg/dL) in the body as a measure of glycemic control.

    Time frame: 6 months

  10. Assess the change in measure of fasting glucose as a measure of glycemic control over the 6 months intervention period.

    To determine the effect of NMN treatment on fasting glucose in the body as a measure of glycemic control.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2026, 43 months after the start.

Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Mar 8, 2023
StartActual
Apr 13, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05759468
Responsible party
Shalendar Bhasin, MD (Principal Investigator, Professor of Medicine, Harvard Medical School Director, Research Program in Men's Health: Aging and Metabolism Co-Director, BWH Center for Transgender Health Director, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital) — Principal investigator
First posted
Mar 8, 2023
Start date
Apr 13, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Shalender Bhasin, MD
Contact
sbhasin@bwh.harvard.edu
6175259150
Nancy Latham, PhD
Contact
nklatham@bwh.harvard.edu
6179999195
Shalender Bhasin, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotinamide Mononucleotide

Start the discussion